Table 1.
Demographics and baseline characteristics, n (%)
|
Patients with APPM and liver disease: APPM cohort, n = 2680
|
Patients without APPM and with liver disease: Control cohort, n = 26299 | |||
|
All patients, n = 2680
|
Patients with fibrosis, n = 96
|
Patients with cirrhosis, n = 26261
|
||
| Total observed patient-years | 6118 | 283 | 5944 | 70261 |
| Median follow-up, yr (IQR) | 1.5 (0.4-3.7) | 2.3 (0.8-4.7) | 1.5 (0.4-3.7) | 2.0 (0.5-4.4) |
| Female sex2 | 840 (31.3) | 41 (42.7) | 815 (31.0) | 8595 (32.7) |
| Median age, yr (IQR)3 | 63.0 (54.0-73.0) | 64.5 (53.0-76.5) | 63.0 (54.0-73.0) | 65.0 (56.0-76.0) |
| 0-14 yr | 14 (0.5) | 6 (6.3) | 10 (0.4) | 49 (0.2) |
| 15-29 yr | 10 (0.4) | 0 | 10 (0.4) | 156 (0.6) |
| 30-44 yr | 183 (6.8) | 10 (10.4) | 177 (6.7) | 1420 (5.4) |
| 45-59 yr | 818 (30.5) | 21 (21.9) | 814 (31.0) | 7516 (28.6) |
| 60-74 yr | 1046 (39.0) | 31 (32.3) | 1029 (39.2) | 9564 (36.4) |
| 75-89 yr | 577 (21.5) | 25 (26.0) | 557 (21.2) | 7090 (27.0) |
| ≥ 90 yr | 32 (1.2) | 3 (3.1) | 29 (1.1) | 504 (1.9) |
| With care needs4 | 547 (20.4) | 33 (34.3) | 528 (20.1) | 4934 (18.8) |
| Median CCI5 (IQR) | 3.0 (1.0-5.0) | 4.0 (1.5-6.0) | 3.0 (1.0-5.0) | 3.0 (1.0-5.0) |
| Most common liver-related comorbidities | ||||
| “Other” liver disease6 | 679 (25.3) | 26 (27.1) | 669 (25.5) | 6298 (23.9) |
| Non-alcoholic steatohepatitis | 17 (0.6) | 1 (1.0) | 16 (0.6) | 150 (0.6) |
| Chronic hepatitis | 12 (0.5) | 0 | 12 (0.5) | 163 (0.6) |
| Respiratory system-related comorbidities | 827 (30.9) | 41 (42.7) | 806 (30.7) | 8333 (31.7) |
| Most common comorbidities | ||||
| Hypertension | 1751 (65.3) | 64 (66.7) | 1710 (65.1) | 17278 (65.7) |
| Type 2 diabetes mellitus | 1103 (41.2) | 40 (41.7) | 1082 (41.2) | 10766 (40.9) |
| Dyslipidaemia | 832 (31.0) | 35 (36.5) | 813 (31.0) | 8932 (34.0) |
| Alcohol-related disorders7 | 650 (24.3) | 17 (17.7) | 649 (24.7) | 6127 (23.3) |
| Heart failure | 605 (22.6) | 21 (21.9) | 591 (22.5) | 6071 (23.1) |
Data are n (%) unless otherwise indicated.
In total, 42 patients with fibrosis progressed to cirrhosis during follow-up and are included in both fibrosis and cirrhosis subgroups.
Patients in the alterations in plasma protein metabolism (AAPM) cohort were significantly younger than patients in the control cohort (Wilcoxon rank-sum test: P < 0.001).
There was no statistically significant difference in the proportion of females between cohorts (Wilcoxon rank-sum test: P = 0.159).
Dummy variable for patients who were classified in any of the five care levels which determine the benefits from long-term care insurance in Germany.
Assessed based on diagnoses observed in the 12 mo before the index date.
Captured using the K76 code in the German Modification of the International Classification of Diseases-10th Revision, and includes central hemorrhagic necrosis of the liver, chronic congestive liver, fatty liver (not otherwise classified), hepatorenal syndrome, liver infarction, peliosis hepatis, portal hypertension, veno-occlusive liver disease and other/unspecified liver disease.
Patients with alcohol-related disorders diagnosed before [1172 (43.7%)] and after [1042 (38.9%)] diagnosis of APPM were detected in the cohort with APPM and liver disease.
CCI: Charlson comorbidity index; IQR: Interquartile range.